Abstract
The growth-promoting effect of Id-1 (inhibitor of differentiation/DNA binding) has been demonstrated in a number of human cancers. However, the mechanisms responsible for its action are not clear. In this study, we report that in prostate cancer cells, Id-1 promotes cell survival through activation of nuclear factor-κB (NF-κB) signalling pathway. After stable expression of Id-1 protein in LNCaP cells, we found that the Id-1 transfectants showed increased resistance to apoptosis induced by TNFα through inactivation of Bax and caspase 3. In addition, in the LNCaP cells expressing ectopic Id-1 protein, we also observed increased NF-κB transactivation activity and nuclear translocation of the p65 and p50 proteins, which was accompanied by upregulation of their downstream effectors Bcl-xL and ICAM-1. These results indicate that the Id-1-induced antiapoptotic effect may be via NF-κB signalling transduction pathway in these cells. In addition, inactivation of Id-1 by its antisense oligonucleotide and retroviral construct in DU145 cells resulted in the decrease of nuclear level of p65 and p50 proteins, which was associated with increased sensitivity to TNFα-induced apoptosis. Our results strongly suggest that Id-1 may be one of the upstream regulators of NF-κB and activation of NF-κB signalling pathway may be essential for Id-1 induced cell proliferation through protection against apoptosis. Our findings also suggest a potential therapeutic strategy in which inactivation of Id-1 may lead to sensitization of prostate cancer cells to chemotherapeutic drug-induced apoptosis.
Similar content being viewed by others
References
Alani RM, Hasskarl J, Grace M, Hernandez MC, Israel MA and Munger K . (1999). Proc. Natl. Acad. Sci. USA, 96, 9637–9641.
Alani RM, Young AZ and Shifflett CB . (2001). Proc. Natl. Acad. Sci. USA, 98, 7812–7816.
Baeuerle PA and Baltimore D . (1996). Cell, 87, 13–20.
Baldwin Jr AS . (1996). Annu. Rev. Immunol., 14, 649–683 .
Baldwin Jr AS, Azizkhan JC, Jensen DE, Beg AA and Coodly LR . (1991). Mol. Cell. Biol., 11, 4943–4951.
Barone MV, Pepperkok R, Peverali FA and Philipson L . (1994). Proc. Natl. Acad. Sci. USA, 91, 4985–4988.
Benezra R, Davis RL, Lockshon D, Turner DL and Weintraub H . (1990). Cell, 61, 49–59.
Chen F, Castranova V and Shi X . (2001). Am. J. Pathol., 159, 387–397.
Desprez PY, Hara E, Bissell MJ and Campisi J . (1995). Mol Cell. Biol., 15, 3398–3404.
Desprez PY, Lin CQ, Thomasset N, Sympson CJ, Bissell MJ and Campisi J . (1998). Mol. Cell. Biol., 18, 4577–4588.
Dhanalakshmi S, Singh RP, Agarwal C and Agarwal R . (2002). Oncogene, 21, 1759–1767.
DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S and Karin M . (1996). Mol. Cell. Biol., 16, 1295–1304.
Gupta S, Afaq F and Mukhtar H . (2002). Oncogene, 21, 3727–3738.
Gurumurthy S, Vasudevan KM and Rangnekar VM . (2001). Cancer Metastasis Rev., 20, 225–243.
Florio M, Hernandez MC, Yang H, Shu HK, Cleveland JL and Israel MA . (1998). Mol. Cell. Biol., 18, 5435–5444.
Hara E, Uzman JA, Dimri GP, Nehlin JO, Testori A and Campisi J . (1996). Dev. Genet., 18, 161–172.
Hara E, Yamaguchi T, Nojima H, Ide T, Campisi J, Okayama H and Oda K . (1994). J. Biol. Chem., 269, 2139–2145.
Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ . (2001). Oncogene, 20, 4188–4197.
Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG . (1993). Cancer Res., 53, 3976–3985.
Kebebew E, Treseler PA, Duh QY and Clark OH . (2000). Surgery, 128, 952–957.
Kim BY, Gaynor RB, Song K, Dritschilo A and Jung M . (2002a). Oncogene, 21, 4490–4497.
Kim D, Xu M, Nie L, Peng XC, Jimi E, Voll RE, Nguyen T, Ghosh S and Sun XH . (2002b). Immunity, 16, 9–21.
Kleeff J, Ishiwata T, Friess H, Buchler MW, Israel MA and Korc M . (1998). Cancer Res., 58, 3769–3772.
Langlands K, Down GA and Kealey T . (2000). Cancer Res., 60, 5929–5933.
Li X and Stark GR . (2002). Exp. Hematol., 30, 285–296.
Lin CQ, Singh J, Murata K, Itahana Y, Parrinello S, Liang SH, Gillett CE, Campisi J and Desprez PY . (2000). Cancer Res., 60, 1332–1340.
Ling MT, Wang X, Tsao SW and Wong YC . (2002a). Biochim. Biophys. Acta, 1570, 145–152.
Ling MT, Wang X, Ouyang X, Lee TKW, Fan T, Xu K, Tsao SW and Wong YC . (2002b). Oncogene, 21, 8498–8505.
Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, Bader BL, Hynes RO, Zhuang Y, Manova K and Benezra R . (1999). Nature, 401, 670–677.
Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin Jr AS and Mayo MW . (2000). Mol. Cell. Biol., 20, 1626–1638.
Maruyama H, Kleeff J, Wildi S, Friess H, Buchler MW, Israel MA and Korc M . (1999). Am. J. Pathol., 155, 815–822.
Norton JD and Atherton GT . (1998). Mol. Cell. Biol., 18, 2371–2381.
Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, Sharrocks AD, Peters G and Hara E . (2001). Nature, 409, 1067–1070.
Ouyang XS, Wang X, Lee DT, Tsao SW and Wong YC . (2001). Carcinogenesis, 22, 965–973.
Ouyang XS, Wang X, Lee DT, Tsao SW and Wong YC . (2002a). J. Urol., 167, 2598–2602.
Ouyang XS, Wang X, Ling MT, Wong HL, Tsao SW and Wong YC . (2002b). Carcinogenesis, 23, 721–725.
Palayoor ST, Youmell MY, Calderwood SK, Coleman CN and Price BD . (1999). Oncogene, 18, 7389–7394.
Parrinello S, Lin CQ, Murata K, Itahana Y, Singh J, Krtolica A, Campisi J and Desprez PY . (2001). J. Biol. Chem., 276, 39213–39219.
Pise-Masison CA, Mahieux R, Jiang H, Ashcroft M, Radonovich M, Duvall J, Guillerm C and Brady JN . (2000). Mol. Cell. Biol., 20, 3377–3386.
Polsky D, Young AZ, Busam KJ and Alani RM . (2001). Cancer Res., 61, 6008–6011.
Raffo AJ, Kim AL and Fine RL . (2000). Oncogene, 19, 6216–6228.
Schindl M, Oberhuber G, Obermair A, Schoppmann SF, Karner B and Birner P . (2001). Cancer Res., 61, 5703–5706.
Sevilla L, Zaldumbide A, Pognonec P and Boulukos KE . (2001). Histol. Histopathol., 16, 595–601.
Shao J, Fujiwara T, Kadowaki Y, Fukazawa T, Waku T, Itoshima T, Yamatsuji T, Nishizaki M, Roth JA and Tanaka N . (2000). Oncogene, 19, 726–736.
Stennicke HR and Salvesen GS . (1997). J. Biol. Chem., 272, 25719–25723.
Takai N, Miyazaki T, Fujisawa K, Nasu K and Miyakawa I . (2001). Cancer Lett., 165, 185–193.
Tanaka K, Pracyk JB, Takeda K, Yu ZX Ferrans VJ, Desphande SS, Ozaki M, Hwang PM, Lowenstein CJ, Irani K and Finkel T . (1998). J. Biol. Chem., 273, 25922–25928.
Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D and Miyamoto S . (1995). Genes Dev., 9, 2723–2735.
Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin Jr AS . (1998). Science, 281, 1680–1683.
Wilson JW, Deed RW, Inoue T, Balzi M, Becciolini A, Faraoni P, Potten CS and Norton JD . (2001). Cancer Res., 61, 8803–8810.
Wu MX, Ao Z, Prasad KV, Wu R and Schlossman SF . (1998). Science, 281, 998–1001.
Zhong H, Voll RE and Ghosh S . (1998). Mol. Cell, 1, 661–671.
Acknowledgements
This work was supported by RGC grants to YC Wong (HKU 7186/99 M, HKU 7314/01 M and HKU 7490/03M) and Area of Excellence Scheme (Project No. AoE/P-10/01).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ling, MT., Wang, X., Ouyang, XS. et al. Id-1 expression promotes cell survival through activation of NF-κB signalling pathway in prostate cancer cells. Oncogene 22, 4498–4508 (2003). https://doi.org/10.1038/sj.onc.1206693
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206693
- Springer Nature Limited
Keywords
This article is cited by
-
ID1 marks the tumorigenesis of pancreatic ductal adenocarcinoma in mouse and human
Scientific Reports (2022)
-
Retraction Note to: Id-1 stimulates cell proliferation through activation of EGFR in ovarian cancer cells
British Journal of Cancer (2021)
-
The role of leukemia inhibitory factor in pathogenesis of pre-eclampsia: molecular and cell signaling approach
Journal of Molecular Histology (2021)
-
Cinchonine induces apoptosis of HeLa and A549 cells through targeting TRAF6
Journal of Experimental & Clinical Cancer Research (2017)
-
Id-1 promotes migration and invasion of non-small cell lung cancer cells through activating NF-κB signaling pathway
Journal of Biomedical Science (2017)